Cargando…

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older

INTRODUCTION: The incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiragami, Makoto, Mizukami, Akiko, Kaise, Toshihiko, Curran, Desmond, Van Oorschot, Desiree, Bracke, Benjamin, Watanabe, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522608/ https://www.ncbi.nlm.nih.gov/pubmed/30929219 http://dx.doi.org/10.1007/s13555-019-0291-4

Ejemplares similares

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis
por: Watanabe, Daisuke, et al.
Publicado: (2018)

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
por: Teng, Lida, et al.
Publicado: (2022)

Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
por: van Oorschot, Desirée A M, et al.
Publicado: (2019)

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
por: McGirr, Ashleigh, et al.
Publicado: (2019)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study
por: Mizukami, Akiko, et al.
Publicado: (2017)

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
por: Curran, Desmond, et al.
Publicado: (2021)

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
por: Van Oorschot, Desirée, et al.
Publicado: (2018)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy
por: Volpi, Antonio, et al.
Publicado: (2019)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

A systematic literature review of herpes zoster incidence worldwide
por: van Oorschot, Désirée, et al.
Publicado: (2021)

Meta-Regression of Herpes Zoster Incidence Worldwide
por: Curran, Desmond, et al.
Publicado: (2021)

Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan
por: Nakamura, Hiroyuki, et al.
Publicado: (2017)

1440. Meta-regression Analysis of Worldwide Herpes Zoster Incidence
por: Yawn, Barbara P, et al.
Publicado: (2021)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
por: Lee, Christa, et al.
Publicado: (2021)

Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children
por: Shiragami, Makoto, et al.
Publicado: (2014)

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)

A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients’ Health-Related Quality of Life
por: Van Oorschot, Desirée, et al.
Publicado: (2022)

Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
por: Shiragami, Makoto, et al.
Publicado: (2015)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005–2014
por: Imafuku, Shinichi, et al.
Publicado: (2018)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)

2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine
por: Schmader, Kenneth E, et al.
Publicado: (2019)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice‐based cohort study
por: Sato, Keiko, et al.
Publicado: (2016)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies
por: Andrew, Melissa K, et al.
Publicado: (2020)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

The temporal impact of aging on the burden of herpes zoster
por: Varghese, Lijoy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r9qa14lug5tng8l5qaakbqqrgh